New Jersey-based Catalent Biologics says it has completed the $14 million expansion of its Bloomington manufacturing site. The company says the 15,000-square-foot expansion includes five new packaging suites and a laboratory to support its packaging capabilities and capacity.
Catalent, a provider of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, says the expansion marks a major milestone for its late-stage and commercial customers and allows the company to focus on complex device assembly and packaging needs at higher volumes.
Catalent says it has developed strategic partnerships with industry leaders to bring new technologies and integrated capabilities to customers with three new state-of-the-art packaging lines. The company says all three high-speed lines are fully qualified and ready to provide customers faster and more flexible packaging solutions for vials, syringes, and devices with no glass-to-glass contact.
Mike Riley, region president of Biologics North America said, “This state-of-the-art equipment adds to our growing network of global packaging capabilities alongside our Brussels, Belgium, and Anagni, Italy drug product manufacturing sites.”
Catalent says its 875,000-square-foot Bloomington facility specializes in sterile formulation and biomanufacturing.